Información del artículo
El Texto completo está disponible en PDF
References
[1.]
C. Mangas, C. Paradelo, J. Rex, C. Ferrándiz.
La biopsia del ganglio centinela: su papel diagnóstico y pronóstico en el melanoma maligno.
Actas Dermosifiliogr, 99 (2008), pp. 331-348
[2.]
C.M. Balch, A.C. Buzaid, S.J. Soong, M.B. Atkins, N. Cascinelli, D.G. Coit, et al.
Final version of the American Joint Committee on Cancer Staging System for cutaneous melanoma.
J Clin Oncol, 19 (2001), pp. 3635-3648
[3.]
R. Essner.
Sentinel lymph node biopsy and melanoma biology.
Clin Cancer Res, 12 (2006), pp. 2320s-2325s
[4.]
C. Ferrándiz, C. Mangas.
Utilidad terapéutica directa de la biopsia del ganglio centinela en pacientes con melanoma.
Med Clin (Barc), 126 (2006), pp. 135-136
[5.]
D.L. Morton, J.F. Thompson, A.J. Cochran, N. Mozzillo, R. Elashoff, R. Essner, et al.
Sentinel-node biopsy or nodal observation in melanoma.
N Engl J Med, 355 (2006), pp. 1307-1317
[6.]
D.L. Morton, A.J. Cochran.
The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma.
Br J Dermatol, 151 (2004), pp. 308-319
[7.]
R. Essner.
Surgical treatment of malignant melanoma.
Surg Clin North Am, 83 (2003), pp. 109-156
[8.]
A. Pizarro, P. Redondo.
Melanoma dissemination and the usefulness of sentinel lymph node biopsy: a reappraisal.
Skin Cancer, 19 (2004), pp. 221-230
[9.]
S.P. Leong.
Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node experience.
Ann Surg Oncol, 11 (2004), pp. 192S-197S
[10.]
C.M. Balch, N. Cascinelli, F.H. Sim.
Elective lymph node dissection. Results of prospective randomised surgical trials.
Cutaneous Melanoma, pp. 379-395
[11.]
J.P. Sleeman.
The lymph node as a bridgehead in the metastatic dissemination of tumors.
Recent Results Cancer Res, 157 (2000), pp. 55-81
[12.]
A. Pizarro.
La biopsia del ganglio centinela desde una perspectiva inmunológica: reticencias injustificadas.
Actas Dermosifiliogr, 96 (2005), pp. 628-630
[13.]
P. Navarro, M. Gómez, A. Pizarro, C. Gamallo, M. Quintanilla, A. Cano.
A role for the E-cadherin cell-cell adhesion molecule during tumor progression of mouse epidermal carcinogenesis.
J Cell Biol, 115 (1991), pp. 517-533
[14.]
J. Palacios, N. Benito, A. Pizarro, A. Suárez, J. Espada, A. Cano, et al.
Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and other pathological features.
Am J Pathol, 146 (1995), pp. 605-612
[15.]
A. Pizarro, C. Gamallo, N. Benito, J. Palacios, M. Quintanilla, A. Cano, et al.
Differential patterns of placental and epithelial cadherin expression in basal cell carcinoma and in the epidermis overlying tumours.
Br J Cancer, 72 (1995), pp. 327-332
[16.]
A. Pizarro.
E-cadherin expression in basal cell carcinoma: association with local invasiveness but not with metastatic inefficiency.
J Cutan Pathol, 27 (2000), pp. 479-480
[17.]
M.B. Lens, M. Dawes, T. Goodacre, J.A. Newton-Bishop.
Elective lymph node dissection in patients with melanoma. Systematic review and meta-analysis of randomized controlled trials.
Arch Surg, 137 (2002), pp. 458-461
[18.]
P.S. Steeg.
Tumor metastasis: mechanistic insights and clinical challenges.
Nat Med, 12 (2006), pp. 895-904
[19.]
S.A. Eccles, D.R. Welch.
Metastasis: recent discoveries and novel treatment strategies.
Lancet, 369 (2007), pp. 1742-1757
[20.]
J.A. Aguirre-Ghiso.
Models, mechanisms and clinical evidence for cancer dormancy.
Nat Rev Cancer, 7 (2007), pp. 834-845
[21.]
F. Meier, S. Will, U. Ellwanger, B. Schlagenhauff, B. Schittek, G. Rassner, et al.
Metastatic pathways and time courses in the orderly progression of cutaneous melanoma.
Br J Dermatol, 147 (2002), pp. 62-70
[22.]
A. Tejera-Vaquerizo, M.V. Barrera-Vigo, I. Fernández-Canedo, N. Blázquez-Sánchez, M. Mendiola-Fernández, A. Fernández-Orland, et al.
Estudio temporal de los diferentes patrones metastásicos en la progresión del melanoma cutáneo.
Actas Dermosifiliogr, 98 (2007), pp. 531-538
[23.]
N. Cascinelli, A. Morabito, M. Santinami, R.M. MacKie, F. Belli.
Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial.
Lancet, 351 (1998), pp. 793-796
[24.]
U. González.
Cloud over sentinel node biopsy. Unlikely survival benefit in melanoma.
Arch Dermatol, 143 (2007), pp. 775-776
[25.]
M.H. Kanzler.
The current status of evaluation and treatment of high-risk cutaneous melanoma. Therapeutic breakthroughs remain elusive.
Arch Dermatol, 143 (2007), pp. 785-787
[27.]
J.M. Kirkwood, J. Manola, J. Ibrahim, V. Sondak, M.S. Ernstoff, U. Rao.
A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma.
Clin Cancer Res, 10 (2004), pp. 1670-1677
[28.]
R.J. Epstein.
Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment.
Clin Cancer Res, 11 (2005), pp. 5337-5341
[29.]
H. Gogas, J. Ioannovich, U. Dafni, C. Stavropoulou-Goikas, K. Frangia, D. Tsoutsos, et al.
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
N Engl J Med, 354 (2006), pp. 709-718
[30.]
N. Medalie, A.B. Ackerman.
Sentinel node biopsy has no benefit for patients whose primary cutaneous melanoma has metastasized to a lymph node and therefore should be abandoned now.
Br J Dermatol, 151 (2004), pp. 298-307
[31.]
D.B. Pharis, J.A. Zitelli.
The management of regional lymph nodes in cancer.
Br J Dermatol, 149 (2003), pp. 919-925
[32.]
K.M. McMasters.
What good is sentinel lymph node biopsy for melanoma if it does not improve survival?.
Ann Surg Oncol, 11 (2004), pp. 810-812
[33.]
M.S. Sabel, K.A. Griffith, A. Arora, J. Shargorodsky, D. Blazer, R. Rees, et al.
Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy.
Surgery, 141 (2007), pp. 728-735
[34.]
R. Essner, R. Scheri, M. Kavanagh, H. Torisu-Itakura, L.A. Wanek, D.L. Morton.
Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection.
Arch Surg, 141 (2006), pp. 877-884
[35.]
B. Badgwell, Y. Xing, J.E. Gershenwald, J.E. Lee, P.F. Mansfield, M.I. Ross, et al.
Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma.
Ann Surg Oncol, 14 (2007), pp. 2867-2875
[36.]
A. Pizarro.
La biopsia del ganglio centinela desde una perspectiva inmunológica: ¿optimismo prematuro?.
Actas Dermosifiliogr, 94 (2003), pp. 60-62
[37.]
S.R. Alonso, L. Tracey, P. Ortiz, B. Pérez-Gómez, J. Palacios, R. Pajares, et al.
A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis.
Cancer Res, 67 (2007), pp. 3450-3460
[38.]
J. Jaeger, D. Koczan, H.J. Thiesen, S.M. Ibrahim, G. Gross, R. Spang, et al.
Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in lasermicrodissected melanoma tissues.
Clin Cancer Res, 13 (2007), pp. 806-814
[39.]
I.J. Fidler.
The pathogenesis of cancer metastasis: the «seed and soil» hypothesis revisited.
Nat Rev Cancer, 3 (2002), pp. 453-458
[40.]
G.P. Gupta, J. Massagué.
Cancer metastasis: building a framework.
Cell, 127 (2006), pp. 679-695
[41.]
W.H. Clark.
Tumour progression and the nature of cancer.
Br J Cancer, 64 (1991), pp. 631-644
[42.]
S.L. Wong, D.L. Morton, J.F. Thompson, J.E. Gershenwald, S.PL. Leong, D.S. Reintgen, et al.
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study.
Ann Surg Oncol, 13 (2006), pp. 809-816
[43.]
R. Essner.
Experimental frontiers for clinical applications: novel approaches to understanding mechanisms of lymph node metastases in melanoma.
Cancer Metastasis Rev, 25 (2006), pp. 257-267
[44.]
M.I. Harrell, B.M. Iritani, A. Ruddell.
Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis.
Am J Pathol, 170 (2007), pp. 774-786
[45.]
C.N. Qian, B. Berghuis, G. Tsarfaty, M. Bruch, E.J. Kort, J. Ditley, et al.
Preparing the «soil»: the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells.
Cancer Res, 66 (2006), pp. 10365-10376
Copyright © 2008. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
